The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable anticipation within the market. A shift away from Schedule I status, often viewed as outdated and hindering progress, could unlock significant opportunities for companies. Reduced regulatory restrictions, alongside greater access to banking and… Read More